4888.T) announced today that it submitted a partial manufacturing and marketing approval">
PULSE NEWS WIRE
Clear, Actionable Intelligence
<2 min
Avg Latency
24/5
Coverage

Pulse News Wire translates Japanese corporate disclosures filed with the Tokyo Stock Exchange's TDNet system into clear, structured English for institutional investors, hedge funds, and asset managers. Every article on this page is derived directly from an official TDNet filing — including earnings reports, M&A announcements, share buybacks, dividend declarations, and governance changes. Japanese corporate governance is governed by the Companies Act and the Financial Instruments and Exchange Act; timely translation of these disclosures provides a material information advantage for cross-border investors monitoring Tokyo-listed equities.

This corporate disclosure from STELLA PHARMA CORPORATION was processed by Pulse News Wire on March 24, 2026. It represents a primary source document for Japanese Corporate sector intelligence, translated directly from an official filing submitted to the Tokyo Stock Exchange TDNet system.

STELLA PHARMA: Seeks Approval for Boron-Based Cancer Drug

TOKYO, Mar 24 (Pulse News Wire) – Stella Pharma Corporation (4888.T) announced today that it submitted a partial manufacturing and marketing approval application to the Ministry of Health, Labour and

View all 4888.T disclosures →

Share this disclosure: Share on X Share on LinkedIn